MUMBAI, Sept 7 An Indian court has ruled in
favour of local drugmaker Cipla in a patent
infringement case filed by Switzerland's Roche Holding AG
over Cipla's cancer drug Erlocip, a senior executive of
the Indian company said.
The Delhi High Court made the ruling a week before India's
Supreme Court is due to begin hearing a patent plea by another
Swiss drugmaker, Novartis AG, over its cancer drug
Glivec. That case is expected to set a precedent for the Indian
drug market, where major western companies are fighting to
protect their intellectual property.
"The court judgement says we have not infringed any patent,"
S. Radhakrishnan, a director on Cipla's board, told Reuters late
on Friday after the Delhi High Court's ruling.
Roche accuses Cipla of infringing its patent on cancer drug
Tarceva, which Cipla sells under the brand name Erlocip.
Roche could not immediately be reached for comment. The
company has the option to challenge the judgement in India's
The ruling comes nearly four years after the court rejected
Roche's attempt to stop Cipla from selling Erlocip in India.
The court, however, said that Roche's patent over Tarceva is
valid in India, media reports said.
(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and